Clinical Trial Update: A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) [Phase 3]

View source ↗

Summary

A Phase 3 trial protocol comparing belantamab mafodotin plus lenalidomide and dexamethasone (BRd) versus daratumumab plus lenalidomide and dexamethasone (DRd) i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Blenrep (belantamab mafodotin)
• DARZALEX (daratumumab)
• DEXAMETHASONE (Dexamethasone)
• Revlimid (lenalidomide)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 3 | Status: RECRUITING